Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:

NCT ID: NCT04530799 Recruiting - Clinical trials for Influenza With Pneumonia

Prospective Observational Trial of IAPA

IAPAFLU
Start date: March 10, 2022
Phase:
Study type: Observational

A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU patients with severe influenza.

NCT ID: NCT04499378 Recruiting - Covid19 Clinical Trials

Tomographic Findings in COVID-19 and Influenza H1N1

Start date: August 15, 2020
Phase:
Study type: Observational

The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to evaluate the association between the radiological CT pattern and the need for invasive mechanical ventilation. A secondary aim is to assess the mortality within the first 28 days of intensive care unit admission.

NCT ID: NCT04497311 Recruiting - Covid19 Clinical Trials

Tomographic Findings in COVID-19 and Influenza

TOMOCOVIDMX
Start date: June 15, 2020
Phase:
Study type: Observational

The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to compare the radiological patterns found in patients with COVID-19 and influenza H1N1. The secondary aims of this study will assess the association between the radiological CT pattern and the need for invasive mechanical ventilation and mortality within the first 28 days of intensive care unit admission.

NCT ID: NCT04494412 Recruiting - Influenza, Human Clinical Trials

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Start date: November 21, 2022
Phase: Phase 2
Study type: Interventional

Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more than or equal to (>=) 6 months of age with hospitalized influenza in the IV zanamivir global development program. However, antiviral treatment of neonates and infants under 6 months of age hospitalized with influenza infection remains a medical unmet need. Given the immaturity of the immune system at this age, there are no licensed influenza vaccines for children aged less than six months old. As a requirement of the Pediatric Investigation Plan European Union (EU), GlaxoSmithKline (GSK) will be conducting this open-label, multi-center, single arm, post-marketing authorization study to evaluate the PK and collect safety and tolerability information of IV zanamivir in hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection. The total duration of study participation for each participant will be up to 24 days with a study treatment period up to 10 days and 14 days of post-treatment follow up. However, for a given participant, the initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests as assessed by the investigator warrant further treatment. DECTOVA is a trademark of GlaxoSmithKline group of companies.

NCT ID: NCT04487041 Recruiting - Human Influenza Clinical Trials

Tfh Dysfunction in HIV and Aging

Start date: October 30, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this research is to evaluate blood samples from HIV infected and non-HIV infected people to understand how aging and HIV infection affect the immune responses (body defenses against infection) to the flu vaccine.

NCT ID: NCT04431050 Recruiting - Clinical trials for Respiratory Syncytial Virus Infections

Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens

SIMPLIFI
Start date: February 24, 2020
Phase:
Study type: Observational

This study evaluates a single use point of care diagnostic test in the diagnosis of influenza and other respiratory viral infections in adults. Participants will have a sample taken from their nose using a swab. The swab will be gently mixed in a liquid solution which will then be transferred into the device for testing.

NCT ID: NCT04367883 Recruiting - COVID19 Clinical Trials

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Start date: March 1, 2020
Phase:
Study type: Observational

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

NCT ID: NCT04336020 Recruiting - Influenza Clinical Trials

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

DETECT
Start date: March 24, 2020
Phase:
Study type: Observational

Develop an app-based nationwide study of individuals who routinely use a smartwatch or other wearable activity tracker to determine if individualized tracking of changes in heart rate, activity and sleep can provide an early indication of influenza-like illnesses (ILI) and possibly other viral infections.

NCT ID: NCT04327791 Recruiting - Influenza Clinical Trials

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

COMBO 1
Start date: April 3, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).

NCT ID: NCT04313946 Recruiting - COVID-19 Clinical Trials

Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays

AI-COVID-Xr
Start date: March 18, 2020
Phase:
Study type: Observational

This project aims to use artificial intelligence (image discrimination) algorithms, specifically convolutional neural networks (CNNs) for scanning chest radiographs in the emergency department (triage) in patients with suspected respiratory symptoms (fever, cough, myalgia) of coronavirus infection COVID 19. The objective is to create and validate a software solution that discriminates on the basis of the chest x-ray between Covid-19 pneumonitis and influenza